Chemed earnings on deck as hospice, plumbing units face tests

Chemed is expected to report Q1 EPS of $5.34 on revenue of $651 million, but analysts have cut EPS estimates 11.53% and revenue estimates 2.46% over the past 60 days. The company enters the print after a Q4 miss, with VITAS and Roto-Rooter both under pressure, though the consensus target of $443 still implies 18.3% upside from the $373.15 share price. Investors will focus on 2026 adjusted EPS guidance of $23.25 to $24.25 and whether recent buyback authorization helps support sentiment.

Analysis

The market is treating this as a binary print, but the more important issue is whether Chemed’s earnings power is becoming more cyclical than the market has historically modeled. If hospice admissions decelerate while plumbing remains weak, the company loses the diversification premium that justified a richer multiple than peers. In that case, buyback support may slow the downside but won’t offset multiple compression if investors start underwriting a lower-quality earnings stream.

The setup also creates a second-order read-through for hospice operators and managed care vendors: if Chemed needs to lean harder on pricing, labor efficiency, or referral economics to defend margins, that pressures smaller competitors first and can accelerate industry consolidation. Conversely, if management can prove admissions durability into the back half, the stock likely reprices quickly because expectations have already been ratcheted down; this is a classic “good enough beats” situation where even a modest guide reset can squeeze shorts.

The key catalyst window is the next 1-2 quarters, not just tonight’s release. The risk case is that guidance gets defended for optics while underlying volume/margin trends continue to drift, forcing another round of estimate cuts and target resets over the next 60-90 days. The contrarian angle is that the selloff may already discount a recessionary plumbing and hospice slowdown, so any evidence of stabilization in either segment could trigger a sharp rerating, especially given the company’s capital return capacity.

Key Decisions for Investors

• Tactically sell/short RY into the print if guidance rhetoric sounds unchanged but segment trends remain soft; use a 2-6 week horizon and target downside to the prior post-earnings gap area, with risk defined by a clean beat-and-raise or credible margin inflection.
• If long-term constructive, buy a call spread on RY rather than stock ahead of earnings to express upside from a stabilization surprise; the setup is asymmetric because consensus is already de-risked, but the premium should be kept small given headline risk.
• Pair trade: long a better-quality healthcare services compounder vs. short RY on a relative basis if you want to isolate execution risk from sector beta; the thesis is that Chemed’s valuation still embeds more consistency than its current operating cadence justifies.
• For event-driven traders, wait 24-48 hours post-earnings before adding risk; if the stock sells off on a modest miss but management does not cut full-year guidance, that is the higher-quality entry point for a mean-reversion trade.
• Use a stop if RY breaks its recent 52-week low on volume after the call; that would signal the market is moving from ‘transitory weakness’ to ‘durable earnings downgrade,’ which usually expands downside over the next quarter.